SARS-CoV-2 cell entry gene ACE2 expression in immune cells that infiltrate the
placenta in infection-associated preterm birth

Phetcharawan Lye[1], Caroline E. Dunk[2], Jianhong Zhang[2], Yanxing Wei[2], Jittanan
Nakpu[1], Hirotaka Hamada[1], Guinever E Imperio[1,2], Enrrico Bloise[1,3], Stephen G
Matthews[1,2,4]**, Stephen J Lye[1,2,4]*,**

[1]Department of Physiology, University of Toronto, Toronto, Ontario, Canada (P Lye,
H Hamada, GE Imperio, E Bloise, SG Matthews, SJ Lye).

[2]Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario,
Canada (J Zhang, Y Wei, J Nakpu, CE Dunk, GE Imperio, SG Matthews, SJ Lye).

[3]Department of Morphology, Federal University of Minas Gerais, Belo Horizonte,
Brazil (E Bloise)

[4]Department of Obstetrics and Gynecology and Department of Medicine, University
of Toronto, Toronto, Ontario, Canada (SG Matthews, SJ Lye).

*Corresponding author

**Contributed equally

The authors report no competing interests.

Correspondence to:

Stephen Lye, Lunenfeld-Tanenbaum Research Institute, Sinai Health System,
Toronto, Ontario, Canada.

Email: lye@lunenfeld.ca

Abstract

COVID-19 infection during pregnancy is associated with an increased incidence of

preterm birth but neonatal infection is rare. We assessed pathways by which SARS-CoV-

2 could access the placenta and contribute to fetal transmission. Placentas from

pregnancies complicated with chorioamnionitis (ChA), exhibited increased expression of

ACE2 mRNA. Treatment of 2nd trimester placental explants with LPS, induced an acute

increase in cytokine expression followed by *ACE2* mRNA. Placental ACE2 protein

localized to syncytiotrophoblast, in fetal blood vessels and M1/M2 macrophage and

neutrophils within the villous stroma. Increased numbers of M1 macrophage and

neutrophils were present in the placenta of ChA pregnancies. Maternal peripheral

immune cells (mainly granulocytes and monocytes) express the *ACE2* mRNA and

protein. These data suggest that in COVID19 positive pregnancies complicated by ChA,

ACE2 positive immune cells have the potential to traffic SARS-CoV-2 virus to the placenta

and increase the risk of vertical transmission to the placenta/fetus.

Keywords: SARS-CoV-2, COVID-19, *ACE2*, Chorioamnionitis, Preterm birth, M1, M2

macrophages, Monocyte, Neutrophil, LPS, Placenta

Introduction

A novel coronavirus SARS-CoV-2 (2019-nCoV) appeared in Wuhan, Hubei

Province, China on December 30, 2019, and spread rapidly around the world (Schwartz,

2020). The acute respiratory syndrome caused by SARS-CoV-2 was named Corona Virus

Disease, COVID-19 by the World Health Organization (WHO). At present there are only

a few reports identifying mother to fetus/neonate vertical transmission of COVID-19

infection (Dong *et al.*, 2020). Facchetti et al (2020) recently reported the presence of a

placenta intervillous inflammatory infiltrate consisting of neutrophils and monocyte-

macrophages expressing activation markers in patients with COVID-19 infection, and

Chen et al (2020) suggested the potential for transmission of SARS-CoV-2 from an

infected mother to her fetus/neonate before birth. There is limited data on whether SARS-

CoV-2 infections increase the risk of complications in pregnancy (Qiao, 2020). A recent

systematic review meta-analysis of 13 publications related to COVID infection in

pregnancy from China suggests a high rate of maternal and neonatal complications in

infected individuals with a preterm birth rate of 20% and a lower neonatal infection rate of

6% (Capobianco *et al.*, 2020).

The immune system is a core component of the maternal-fetal interface. Disruption

of the immune system of a pregnant woman, as in the case of bacterial infection, places

the mother and fetus/neonate at risk of other infections, such as viruses, which can impact

the course of pregnancy for both mother (e.g. preterm birth) (Silasi *et al.*, 2015) and

fetus/neonate (e.g. systemic inflammatory response syndrome) (Francis *et al.*, 2019).

Additionally, it has been suggested that viral infection of the placenta modifies the immune

response to bacterial products by destroying the normal 'tolerance' to LPS and

aggravates the inflammatory response, which in turn leads to preterm labor (Cardenas *et*

al., 2011; Kwon *et al.*, 2014). Immune cells at the maternal-fetal interface play a critical

role in a successful pregnancy. In the first trimester they contribute to remodelling of the

uteroplacental circulation (Hazan 2010; Smith 2009), and at term an influx of maternal

peripheral monocytes into the decidua and myometrium leads to their differentiation into

macrophage which generate inflammatory mediators that contribute to the initiation of

labour (Hamilton *et al.*, 2012; Shynlova *et al.*, 2020). However, these cells also contribute

to pathologies of pregnancy. For example, in cases of acute chorioamnionitis bacterial

infection of the fetal membranes and/or placenta results in an increased influx of maternal

neutrophils and monocytes into these tissues where the latter differentiate into classical

activated inflammatory macrophage (Kim *et al.*, 2015; Cappelletti *et al.*, 2020). The

potential adverse consequences to the fetus of placental infection and sensitization to

maternal-fetal viral transmission and the mechanisms by which this might occur require

further investigation.

SARS-CoV-2 cell entry is mediated through angiotensin-converting enzyme 2

(*ACE2*), a protease responsible for the conversion of Angiotensin 1-8 (Ang II) to

Angiotensin 1-7 (Ang 1-7) (Vickers *et al.*, 2002; Jia *et al.*, 2005). Interactions were

identified between the SARS-CoV spike protein and its host receptor ACE2, which

regulate both the cross-species and human-to-human transmission of SARS-CoV (Wan

et al., 2020), and SARS-CoV-2, and share the same receptor, ACE2 (Zhang *et al.*,

2020a). The SARS-CoV spike protein is known to bind ACE2 on the surface of the host

cell via its subunit S1, and then fuse to viral and host membranes through subunit S2.

Viral attachment is facilitated by two domains in subunit S1, which are from different

coronaviruses (Li, 2016). It is currently unknown if SARS-CoV-2 binds in this same

fashion. The expression and distribution of ACE2 has been reported in human fetal heart,

kidneys, liver, lung, and placenta (Crackower *et al.*, 2002; Hamming *et al.*, 2004; Pringle

et al., 2011a). *ACE2* mRNA expression has also been found in early gestation placenta

(Pringle *et al.*, 2011a; Bloise *et al.*, 2020). In addition, ACE2 protein levels were found to

be abundant in the syncytiotrophoblast layer (STB) and villous stroma, while less intense

in the trophoblast layer (CTB) (Pringle *et al.*, 2011a). The STB provides the interface

between the maternal blood, containing immune cells, and the extraembryonic tissues

and fetus (Knöfler *et al.*, 2019; Facchetti *et al.*, 2020). Interestingly activated

macrophages in patients with heart failure have been shown to express high levels of the

SARS-CoV-2 receptor, *ACE2* (Keidar *et al.*, 2005). Furthermore, in patients with chronic

obstructive pulmonary disease (COPD) activation of neutrophils, NK cells, Th17 cells,

Th2 cells, Th1 cells, dendritic cells, and TNFα secreting cells can be induced by

overexpression of ACE2 leading to a severe inflammatory response (Li *et al.*, 2020a).

Since these immune cells can potentially engage the SARS-CoV-2 virus, they may also

represent a reservoir for the virus and a vector for the virus to infect the placenta/fetal

membranes in cases of chorioamnionitis.

We hypothesize that the presence of an intrauterine bacterial infection will activate

peripheral maternal macrophage and neutrophils and cause them to target the uterus and

intrauterine tissues. If these immune cells express the SARS-CoV-2 cell entry protein,

ACE2, then these cells have the potential to transport virus to the placenta and thereby

increase the risk of placental infection and vertical transmission of the virus to the fetus.

Results

Chorioamnionitis and LPS exposure are associated with increased placental *ACE2*

expression and an inflammatory cytokine/chemokine response.

Placental *ACE2* mRNA expression was significantly increased ($P<0.01$) in pregnancies

complicated with PTB in the presence of ChA compared with PTB alone or with

uncomplicated spontaneous vaginal delivery (SVD) or not in labour (elective caesarean

section, ELCS) term pregnancies (Figure 1A). Placental mRNA expression of *CCL2* was

also significantly increased in ChA (*P*<0.05) compared to all other groups but there was

no significant increase in *IL6/8* mRNA expression (Figure 1C-D).

Figure 1. *ACE*, and chemokine mRNA expression is increased in placenta from preterm labor with
chorioamnionitis (ChA). Bar charts show the relative levels of *ACE2* **(A)**, *CCL2* **(B)**, *IL-6* **(C)**, and *IL-8* **(D)**
mRNA in placentas from PTB, ChA, SVD and ELCS deliveries, assessed by real time qPCR. Data are
normalized by the geometric mean of *TOP1* and *YWHAZ* (reference genes), N=6-7/group. Statistical
differences were tested by Tukey's multiple comparisons test. Data are presented as mean ± SEM. Different
letters indicate a difference between groups of p<0.05.

Treatment of 2nd trimester placental explants with LPS (10 µg/mL) from elective

terminations of healthy normal pregnancies resulted in a rapid (4 hour) significant

increase in placental expression of cytokine (*IL-6/8* and *TNFα* mRNA; *P<0.05*) (Figure

2D-E), as well as higher (but non-significant expression of the chemokine *CCL2* (P=0.06))

(Figure 2B). Cytokine/chemokine expression returned to basal levels 24 hours post-LPS

treatment, at which time expression of *ACE2* mRNA in the placental explants increased

significantly (p<0.05) (Figure 2A).

Figure 2. Effect of LPS on *ACE2, CCL2, IL-6/8* and *TNFα* mRNA expression in second trimester

human placental explants. Second trimester placental explants were treated with LPS (10 µg/mL), or

vehicle for 4 and 24 hours and mRNA levels of *ACE2* **(A)**, *CCL2* **(B)**, *IL-6* **(C)**, *IL-8* **(D)** and *TNFα* **(E)**, were

quantified by qPCR (n=5/group). Data are normalized by the geometric mean of *TOP1* and *TBP* (reference

genes). Data are expressed as means ± SEM. Statistical differences were tested using a paired *t*-test.

*p<0.05, versus vehicle.

In contrast to the elevated expression of *ACE2* mRNA, we did not detect any increase in

ACE2 protein within the placentas of preterm pregnancies associated with ChA, although

the levels of ACE2 protein in preterm placentas (with or without ChA) were significantly

higher (p<0.05) than in placentas at term in the presence or absence of labour (Figure

3B).

Figure 3. Placental ACE2 protein levels are increased in PTB with/without chorioamnionitis (ChA) as compared to term. Protein lysates of placentas from PTB, ChA, ELCS and SVD deliveries were assessed for level of ACE2 protein by western blotting. **(A)** Representative western blot images and **(B)** densitometric analysis of ACE2 protein level, normalized by *β*-actin (loading control for protein), N = 6/group. Statistical differences were tested by Tukey's multiple comparisons test. Data are presented as mean ± SEM. Different letters if p<0.05.

Since ACE2 total protein was not increased in ChA placentas, we next determined the localization of ACE2 protein in the placentas from complicated and uncomplicated pregnancies. This analysis revealed expression of ACE2 in the syncytiotrophoblast (STB), which is the fetal tissue in direct connection with maternal blood and in the fetal blood vessels within the placental villous core. We also observed the presence of ACE2 immunoreactivity in histologically-identified macrophages within the placental villous stroma and in association with perivascular cells surrounding the fetal blood vessels and in some fetal blood cells (Figure 4A). ACE2 expression was also present in extravillous trophoblast (EVT) (Figure 4B) and in decidual stromal cells within the placental basal plate (Figure 4C), as well as immune cells within maternal blood present in the intervillous space (Figure 4D).

Figure 4. ACE2 localization in the placenta and in maternal intervillous immune cells. Representative images of ACE2 immunostaining in a placenta from an uncomplicated PTB delivery (**A**) ACE2 staining was localized predominantly in the syncytiotrophoblast layer (STB), fetal blood vessel (pFECs) and fetal hoefbauer cells (MΦ) of the placental villi. (**B**) ACE2 also localised to extravillous trophoblast (EVT) within the basal plate of the placenta and in (**C**) decidual stromal cells. (**D**) ACE2 expression in maternal neutrophils of maternal blood clot adjacent to the decidua, Sections were counter-stained with hematoxylin. N=6/group. Scale bar represents 100μm.

The finding of ACE2 expression in histologically-identified immune cells within the placenta led us to undertake further characterization of these cells in placentas from pregnancies complicated by PTB, in the presence or absence of ChA, as well as term pregnancies with and without the onset of labour. We used monoclonal antibodies specific

for CD68 (which detect the macrophage population); MHC-II - a marker of M1

macrophage; CD206 - a marker of M2 macrophage; and neutrophil elastase (NE) - a

marker of neutrophils. Representative images of immunohistochemical staining revealed

expression of ACE2 was localized to syncytiotrophoblast of all pregnancy groups (Figure

5 A-D) with a reduced intensity of staining in term groups than in preterm groups. ACE2

staining was also apparent in stromal cells which resembled macrophage and neutrophils

(shown in Figure 5 E-T). Staining with CD68 revealed the presence of macrophage within

the placental villous of all pregnancy groups (Figure 5 E-H) and further analysis identified

these to be both M1 (inflammatory) and M2 (angiogenic) sub-types. (Figure 5 I-P). The

M1 macrophage were present throughout the stroma as well as being associated with

fetal blood vessels. Staining with NE detected the presence of neutrophils within the

placental vasculature and villi of all pregnancy groups (Figure 5 Q-T). The distribution of

these immune cells did not appear to be equal across the patient groups, therefore we

sought to quantify their number using Image analysis. Total macrophage numbers were

similar in ChA and PTB control groups however, both of these groups had higher numbers

of macrophage than the term groups (SVD, ELCS; (p<0.01) (Figure 5U). In contrast, the

number of M1 macrophages was significantly increased (p<0.001) in ChA patients

compared to PTB, SVD and ELCS groups (Figure 5V). Whereas, the number of M2 was

significantly higher (p<0.001) in PTB patients compared to ChA, SVD and ELCS groups

(Figure 5W). Quantification of neutrophil numbers across patient groups revealed

significantly higher numbers in ChA pregnancies than in the PTB, SVD or ELCS groups

(Figure 5X; p<0.001).

Figure 5. Localization and quantitation of placental ACE2, CD68 (macrophage marker), MHC-II (M1 marker), CD206 (M2 marker) and neutrophil (NE) staining in complicated and uncomplicated pregnancies. Representative images of ACE2 **(A-D),** M1 **(MHCII E-H)**, M2 **(CD206 I-L)**, CD68 **(M-P)**, and NE **(Q-T)** staining in preterm and term placentas (N=6 in each group). Inserts (bottom left) in H mouse IgG1 and T rabbit IgG1 isotype control staining. Scale bar represents 50μm. Image analysis quantitation of positively stained immune cells as a proportion of the total cells number was performed on a randomly selected 5% of the total tissue area of each placental section. (**U**) CD68 (**V**) M1 (**W**) M2 (**X**) NE. Statistical

differences were tested by Tukey's multiple comparisons test. Data are presented as mean ± SEM. Different

letters represent values significantly $p<0.05$.

Next we determined whether ACE2 is localized within infiltrated immune cell populations

in the ChA placenta, by undertaking co-localization immunofluorescence analysis of

ACE2 and CD68 (macrophage), MHC-II (M1), CD206 (M2) and NE (neutrophil) markers.

Co-localization of ACE2 in macrophages (M1 and M2) and neutrophil was detected,

confirming our previous histological findings that infiltrated macrophages within the

placenta express ACE2 and also identifying infiltrating placental neutrophils as

expressing ACE2. Immune cells expressing ACE2 were localized in the villous stroma

and adjacent to fetal blood vessels. Only a subset of each of immune cells expressed

ACE2 (Figure 6 A-L).

Figure 6. Co-localization of SARS-CoV-2 associated cell-entry protein, ACE2, within specific immune cell populations in ChA placenta. Representative images of ACE2, CD68, M1, M2 and NE staining in immunofluorescence (ACE2; red color and M1, M2, macrophage and NE; green color), macrophage co-staining with ACE2 **(A-C)** M1 co-staining with ACE2 **(D-F)**, M2 co-staining with ACE2 **(G-I)** and neutrophil co-staining with ACE2 **(J-L)**. Co-localization of ACE2 and markers of macrophage and neutrophil confirmed the ACE2 localization within placental macrophages and neutrophils. ACE2 expressing immune cells were present in the villous stroma and adjacent to fetal blood vessels. Only a subset of each of immune cells expressed ACE2. Arrows show ACE2 staining within CD68, M1, M2 and NE stained cells. Sections were counter-stained with DAPI (blue color) or co-staining (yellow color). Inserts (bottom left) in **(C)** mouse and rabbit IgG1 isotype control and **(L)** rabbit IgG1 isotype control staining. N=3/group. Scale bar represents 12 µm.

Expression of *ACE2*/ACE2 in circulating maternal immune cells.

Expression of *ACE2* mRNA was detected in circulating granulocytes, monocytes and

lymphocytes from pregnant women, though levels were quite variable and were not

significantly different across cell types (Figure 7A). Flow cytometry also revealed that

ACE2 was expressed in fractions of circulating granulocytes, monocytes and neutrophils.

A greater fraction of circulating granulocytes were found to be positive for ACE2 than

lymphocytes, but not monocytes (p<0.05; Figure 7B).

Figure 7. The surface expression of ACE2/*ACE2* on circulating granulocytes, monocytes and

lymphocytes in pregnant women.

(A) The relative expression of *ACE2* mRNA on granulocytes, monocytes and lymphocytes in maternal

peripheral blood. There are no different between all of group (N=4/group). Statistical differences were tested

by Tukey's multiple comparisons test. Data are presented as mean ± SEM. **(B)** Peripheral human blood
cells were stained with anti-human ACE2 and CD45 antibodies. The percentage of ACE2+ cells was
calculated according to the gating of viable CD45+ granulocytes, monocytes and lymphocytes. Statistical
analyses were performed by R software (3.4.3). Multiple comparisons were conducted by Kruskal-Wallis
test and Wilcoxon test was followed to examine the statistical difference between two groups. N=6/group.
*, $p < 0.05$.
246

Discussion

In this study we provide evidence that under conditions of intrauterine

infection/inflammation there is an influx of ACE2 expressing neutrophils and macrophage

into the placenta. We suggest that this is a potential mechanism by which maternal-fetal

vertical transmission could occur in COVID 19 infected pregnancies.

We first demonstrated that *ACE2* mRNA levels were increased in the placenta of

pregnancies complicated by chorioamnionitis compared to placentas from patients of

similar gestational age with no evidence of infection, or from term pregnancies (collected

from non-laboring or laboring deliveries). Despite this increase in mRNA, the expression

of ACE2 total protein levels (measured by WB) was not different in the placenta from

patients with PTB and chorioamnionitis compared to those from PTB without

chorioamnionitis, although both preterm groups expressed higher levels of ACE2 than

placentas from patients at term, in the presence or absence of labour. Previously, it has

been reported that there is minimal expression of ACE2 mRNA in the placenta throughout

pregnancy (Pringle *et al.*, 2011b; Bloise *et al.*, 2020; Li *et al.*, 2020b). However, we

recently demonstrated that placental expression of *ACE2* mRNA is gestational-age

dependent with the highest levels in early pregnancy and low to undetectable levels

towards term (Bloise *et al.*, 2020). Our current data suggest a similar gestational-age
dependence pattern for ACE2 protein.

We found differences in the cellular distribution of ACE2 in the placenta of patients
with ChA. Immunohistochemical analysis localized ACE2 to the STB layer, which is
exposed to the maternal circulation as well as in the vascular endothelium of the fetal
circulation. Staining was also present in extravillous trophoblast (EVT), and decidual
stromal cells. Our findings are consistent with other studies that ACE2 is highly expressed
in cells at the maternal-fetal interface including, STB, endothelial and perivascular cells
and EVT (Valdés *et al.*, 2006). Acute chorioamnionitis refers to the presence of intra-
amniotic infection or "amniotic fluid infection syndrome" (Romero *et al.*, 1992; Kim *et al.*,
2015). Acute chorioamnionitis can also occur in the absence of demonstrable
microorganisms with "sterile intra-amniotic inflammation", and is induced by "danger
signals" or DAMPs released under conditions of cellular stress, injury or death (Romero
et al., 1992; Gomez-Lopez *et al.*, 2019). The characteristic histologic and defining
features of acute chorioamnionitis is a diffuse infiltration of neutrophils into the fetal
membranes (Redline *et al.*, 2003; Kim *et al.*, 2015). All of the placentas in the ChA group
were confirmed, by a placental pathologist, to be Grade 1/2, stage 2/3 with fetal
inflammation of the membranes (amnion and chorion) and umbilical cord (Table 1).
Importantly, we noted expression of ACE2 in immune cells within the ChA placenta.
These cells were characterized to be predominantly M1 macrophage and neutrophils,
many of which were found in close association or within the wall of fetal blood vessels.
Quantification of the number of these cells in the placenta from all patient groups
revealed, as expected, significantly greater numbers of these immune cells in

pregnancies complicated by acute stage 2/3 ChA than the other pregnancy groups. A

recent study has shown that both maternal and fetal neutrophils are present in the

amnionitic fluid of women with a confirmed intraamniotic infection and/or inflammation

(Gomez-Lopez *et al.*, 2017). We did not confirm that the immune cells within the placental

villi were of maternal or fetal origin in this study. However, we did also observe a maternal

intervillous infiltrate of ACE2 expressing maternal neutrophils and macrophage in the ChA

placenta. Further, mRNA and flow cytometric analysis of ACE2 expression by specific

immune subsets in maternal peripheral blood revealed expression of the SARS CoV-2

cell entry protein in neutrophils, monocytes and lymphocytes, with the fractions of

neutrophils expressing ACE2 being significantly higher than in lymphocytes, but not

monocytes. The surface expression of ACE2 on these peripheral immune cells, provides

a route by which the virus could enter these cells in the peripheral circulation. Since

intrauterine infection (as in the case of chorioamnionitis) leads to activation and targeting

of maternal immune cells (particularly neutrophils and monocytes) to the placenta

(Glauser *et al.*, 1991; Liu *et al.,* 2018), this would provide a direct path which might

facilitate the transmission of viral particles into the placental bed, and subsequently to the

fetus. Thus, maternal immune cells could act as the vector for SARS CoV-2 to infect the

placenta and or fetus.

Our data showing that LPS treatment (a model of bacterial infection and

chorioamnionitis) of second trimester placental explants induces a rapid induction of

chemokine/cytokines (*CCL2, IL-6/8* and *TNF*α) transcripts and *ACE2* mRNA at 24 hours

provides support that placental bacterial infection might increase the opportunity for

placental infection by SARS CoV-2. Since syncytiotrophoblast and placental resident

immune cells express ACE2 two potential routes for viral infection might exist, one

through direct interaction between virus and the outer (syncytial) surface of the placenta

and one through the influx of virus containing immune cells. Moreover, since the activated

immune cells infiltrating into the placenta can release proinflammatory cytokines this

might further enhance placenta *ACE2* mRNA expression (Liu *et al.*, 2018). Whether

bacterial LPS can sensitize the placenta to infections by SARS-CoV-2 is not known, and

requires further study.

There is conflicting data as to whether SARS-CoV-2 can be transmitted to the fetus

through the placenta in women with COVID-19. Early reports of obstetric and neonatal

outcomes of pregnant women from China with COVID-19 suggested that SARS-CoV-2

infection in pregnancy results in limited neonatal infection (Rasmussen *et al.*, 2020; Zhang

et al., 2020b). However, an increasing number of studies reporting neonatal cases with

congenital or intrapartum infection. So far, 10 infants with SARS-CoV-2 infection meet

these criteria based on a classification system defined by Shah et al. (Shah *et al.*, 2020)**.**

Notably, a clinical case report revealed that a neonate born to a COVID-19 infected

pregnant woman was tested positive for SARS-CoV-2 after 36 hours of postnatal life

(Wang *et al.*, 2020), which meets the criteria of intrauterine transmission (Blumberg *et al.*,

2020). In addition, in one preterm pregnancy case, the baby tested negative for COVID-

19 at birth, and positive 24 hours later (Zamaniyan *et al.*, 2020). Three other neonates

showed increased immunoglobulin M (IgM) antibodies specific to COVID19 at birth (Zeng

et al., 2020). There is also a growing body of evidence demonstrating infection of the

placental membrane and the villous trophoblasts, a recent electron microscopy study has

demonstrated the presence of SARS-CoV-2 in placental STB (Algarroba *et al.*, 2020) and

Baud et al have reported a case of SARS-CoV-2 positivity in the placental submembranes

and cotyledons together with mixed inflammatory infiltration and funicity in pregnant

woman in the second trimester (Baud *et al.*, 2020). In this case, placental infection of

SARS-CoV-2 was confirmed by the virologic findings from specimen obtaining from the

fetal surface. Previously, various pathways of viral transplacental migration were

concluded based on the studies of Zika virus, including transmission from maternal blood

to EVT, transcytosis via syncytiotrophoblast-expressed receptors, or spreading by

infected maternal immune cells (Chen *et al.*, 2020; Karimi-Zarchi *et al.*, 2020).These data

support our hypothesis of an increased risk of placental and fetal transmission of SARS-

CoV-2 in cases of intrauterine infection/inflammation and chorioamnionitis.

In conclusion, our data show that the presence of an intrauterine bacterial infection

results in the infiltration of ACE2 expressing maternal macrophage and neutrophils into

and across the placental tissues (Figure 8). These ACE2 expressing immune cells have

the potential to transport virus to the placenta in cases of COVID-19 infection in pregnancy

and increase the risk of placental infection and vertical transmission of the virus to the

fetus.

Figure 8. Schematic model by which maternal immune cells could bring SARS-CoV-2 to the placenta and increase risk of vertical transmission in pregnancies complicated by intrauterine infection. Intrauterine bacterial infection, such as occurs in chorioamnionitis (ChA), leads to increased expression and release of chemokine/cytokines by the placenta that in turn induce activation of maternal immune cells, notably M1 macrophage and neutrophils. These cells then target the sites of infection in the placenta/fetal membranes. Subsets of these immune cells express the SARS-CoV-2 cell entry protein, ACE2, and thus are targets for viral uptake in women infected with SARS-CoV-2. The virus may then be hypothetically transported to the placenta increasing the potential for vertical transmission of the virus to the fetus. MAT= maternal blood, FV= fetal vessel, MΦ= M1 macrophage, NE= neutrophil, STB= syncytiotrophoblast, layer CT= cytrophoblast.

363 **Methods**
364

Ethical Approval

This is a cross-sectional study involving placental tissue collection from pregnancies

(25.3-36.0 weeks' gestation) complicated by preterm birth (PTB; N=12) or preterm birth

with chorioamnionitis (ChA; N=12) or from term pregnancies (>37 weeks' gestation) from

healthy women in labour (vaginal delivery, SVD; n=12) or not in labour (elective

caesarean section, ELCS; N=12). Second trimester human placental tissues were

collected at 16–20 weeks of pregnancy (N=5/group). All clinical information is depicted in

Table 1.

Table 1. Clinical profile of placental tissues. BMI, (Body Mass Index); V, (Vaginal), C,
(Caesarean section with no labor); CL, (Caesarean section with labor); S1, (Stage1); S2,
(Stage2); S3, (Stage3); Y/N, (Yes/No).

	PTB (N=12)	ChA (N=12)	ELCS (N=12)	SVD (N=12)
Maternal Characteristics				
Maternal Age (years)	29.6 ± 1.83 (21-43)	28.5 ± 2.25 (17-40)	35.8 ± 0.85 (34-42)	32.4 ± 1.06 (27-43)
Labor (Y/N)	10:2	11:1	0:12	12:0
BMI	22.4 ± 1.18 (18.26-29.75)	23.8 ± 1.12 (18.30-29.75)	22.6 ± 1.77 (15.24-32.44)	23.2 ± 1.34 (19.08-32.91)
Fetal Characteristics				
Gestational age (weeks)	31.7 ± 0.93 (25.3-36.0)	29.3 ± 1.01 (26-33)	38.6 ± 0.30 (37-41)	39.0 ± 0.32 (37-40.4)
Mode of Delivery (V:C:CL)	2:1:9	5:1:6	0:12:0	12:0:0
Neonatal sex (Male/ Female)	9:3	8:4	6:6	7:5
Pathology Characteristics				
Chorioamnionitis (S1, S2, S3)	No	1:10:1	No	No
Glucocorticoids treatment	Yes	Yes	No	No

Human peripheral blood was collected from normal pregnant women at 10-14 weeks of

pregnancy (N=6). All tissues and peripheral blood were provided by the Research Centre

for Women's and Infants' Health Bio Bank program at Sinai Health System and are

collected following informed written consent (process n# 20-0101-E) and in adherence

with the policies of the Sinai Health System and the University of Toronto Research Ethics

Board and in accordance with the Helsinki declaration on the use of human tissues.

Human Placental Explant Culture

Second trimester human placentae (16 to 20 weeks) from the elective termination of

singleton pregnancies were used to set up the floating explant culture as described earlier

(Lye *et al.*, 2015). Briefly, placental specimens were placed into 1% phosphate-buffered

saline (PBS) with Ca^{2+} and Mg^{2+} and transported to the laboratory. Tissues were

dissected into villous clusters of approximately 15 to 30 mg, and three villous explants

were cultured per well in 12-well plates that contained Dulbec-co's modified Eagle's

medium/F12, Normocin antibiotic (Invivogen, San Diego, CA), and 1 insulin, transferrin,

and selenium-A (Invitrogen, Grand Island, NY) that was previously equilibrated at 8% O_2

(CO_2, 37 °C) for 24 hours. Explants were cultured for 24 hours and then randomly divided

into treatment groups. Explants were treated with LPS from Escherichia coli (10 µg/mL

L4391, Sigma-Aldrich, St. Louis, MO) or vehicle for 4 or 24 hours (Lye *et al.*, 2015).

Explants were then collected and stored at 80°C for total RNA.

Immunohistochemistry

Placental tissues (N=5/6group) were processed for immunohistochemical analysis as

previously described (Lye *et al.*, 2019). Briefly, slides were deparaffinized, rehydrated,

and subjected to heat mediated antigen retrieval with 10mM sodium citrate Ph6.0 for

CD206 and neutrophil primary antibodies, or 1mM EDTA Ph9.0 for MHC-II, CD68 and

ACE2. After blocking with Dako protein block (Dako, Mississauga, ON, Canada), the

slides were incubated overnight at 4°C with primary antibodies: anti-rabbit ACE2 (1:200,

ab15348, Abcam, Toronto, ON, Canada USA) anti-rabbit MHC-II (M1 marker) (1:400,

ab180779, Abcam), anti-rabbit mannose receptor (CD206 (M2),1:200, ab64693, Abcam),

anti-mouse CD68 (macrophage) (1:100, Dako), anti-rabbit neutrophil (NE)(1:100,

ab21595, abcam) was added instead of the primary antibody. After incubation, the slides

were washed and incubated with the corresponding biotinylated secondary antibody

(1:300, 1 hour, Dako). Sections were washed in 1× PBS (3 × 5 min) and incubated with

streptavidin-HRP (1 h; Dako); immunostaining was detected with the peroxidase

substrate kit DAB (Dako). The slides were counterstained with hematoxylin, dehydrated

in ascending concentrations of ethanol, and cover slipped with mounting medium.

Visualization was undertaken with an Olympus BX61 upright, motorized microscope, and

representative images were captured using an Olympus DP72 digital camera (Olympus,

Tokyo, Japan. Negative controls were performed using either isotype Mouse IgG1 or

rabbit IgG/IgG1 antibodies.

Image Analysis and Quantification

Quantification of macrophages subtypes and neutrophils in placental tissues (N=5-

6/group) were performed using an Olympus BX61 microscope equipped with an Olympus

DP72 camera, and the newCAST software (Visopharm). Counts were performed as

previously described (Dunk *et al.*, 2019), using a standard protocol that assigned random

counting frames covering 5% of each total masked tissue area. Brown, positively-staining

cells and blue, negatively-staining cells (haematoxylin-stained) were counted at 10X

magnification. A positively stained ratio was generated by dividing the total numbers of

brown, positively-stained cells by the total number of cells counted in the tissue area).

Double immunofluorescence staining

Different protocols were used for the simultaneous detection of two antigens depending

on the availability of primary antibodies raised in the same or different species. For the

localization of ACE2+CD68 (primary antibodies different species), immunofluorescence

experiments were performed as described previously (Nadeem *et al.*, 2013). In brief, ChA

placental tissue slides were deparaffinized, rehydrated, and subjected to heat mediated

antigen retrieval with 1mM EDTA Ph9. Autofluorescence was reduced using 0.1% Sudan

Black in 70% ethanol (1 minute) and non-specific binding was blocked using 0.1% BSA,

0.3% Triton X-100 and 1% donkey serum in PBS for 1 hour. Placental slides were

incubated with primary antibodies ACE2 (1:100, ab15348, Abcam), anti-mouse CD68

(1:100, Dako), anti-mouse IgG1 (Dako) and anti-rabbit Igg1 (ab171870, Abcam) added

as an isotype control overnight at 4°C. Subsequently, ACE2 + CD68 slides were washed

three times and incubated with fluorescent secondary antibodies, using either the anti-

mouse Alexa 488 (1:1000) or the anti-rabbit Alexa 594 (1:1000) secondary antibodies

(Thermo Fisher Scientific and counterstained with 1 µg/mL of DAPI, for 1 hour).

For the localization of ACE2+MHC-II (M1), ACE2+CD206 (M2) and ACE2+Neutrophil

elastase (NE) (primary antibodies the same species), immunofluorescence experiments

were performed as described previously (Salio *et al.*, 2005; Dunk *et al.*, 2018; Choudhury

et al., 2019). In brief, ChA placental slides were deparaffinized, rehydrated, and subjected

to antigen retrieval with 1mM EDTA Ph9.0. Autofluorescence was reduced using 0.1%

Sudan Black in 70% ethanol (1 minutes) and non-specific binding was blocked using 0.1%

BSA, 0.3% Triton X-100 and 1% donkey serum in PBS for 1 hour. Placental tissues slides

were incubated with primary antibodies ACE2 (1:100, ab15348, Abcam) overnight at 4°C.

Subsequently, ACE2 slides were washed three times and incubated with fluorescent

secondary antibodies using anti-rabbit Alexa 594 (1:1000) (Thermo Fisher Scientific for 1

hour). Slides were washed three times and blocked with 0.1% BSA, 0.3% Triton X-100

and 5% goat serum in PBS for 1 h. Slides were incubated with primary antibodies anti

rabbit-MHC II (M1) (1:100, Abcam), anti-rabbit mannose receptor (CD206, M2,1:100,

Abcam) anti-rabbit NE (1:100, Abcam) and anti-rabbit IgG1 (Abcam) added as an isotype

control overnight at 4°C. Slides were incubated with the corresponding biotinylated

secondary antibody (1:300, 1 h, Dako) then washed three times and incubated with

Streptavidin-Alexa488 (1:2000, Thermo Fisher Scientific and nuclei were stained with 1

µg/mL of DAPI, for 1 h). All slides from the primary antibodies as the same or different

species were washed three times. Fluorescent microscopy was performed using a

spinning disc confocal microscope at various magnifications.

Quantitative Real Time PCR (qPCR)

Total RNA was isolated from flash frozen, stored in -80C placental specimens using

the RNeasy Plus Universal Mini Kit (73404, Qiagen, Toronto, ON, Canada), as previously

described (Lye *et al.*, 2019). RNA concentration and purity were assessed using a

NanoDrop1000 Spectrophotometer (Thermo Scientific). RNA was reverse transcribed

into cDNA using the iScript Reverse Transcription Supermix (Bio-Rad). *ACE2*, *IL-6*, *IL-8*,

TNFα and *CCL2* mRNA levels were measured by qPCR using SYBR Green reagent

(Sigma-Aldrich) and the CFX 380 Real-Time system C1000 TM Thermal Cycler (Bio-

Rad), with the following cycling conditions: initial denaturation at 95 °C (2 min) followed

by 39 cycles of denaturation at 95 °C (5 s) and combined annealing and extension at 60

°C (20 s). Gene expression was normalized to the geometric mean of selected reference

genes, including DNA topoisomerase 1 (*TOP1*) and the zeta polypeptide (*YWHAZ*) which

had stable expression across pregnancies complicated by PTB or ChA or from SVD or

ELCS groups. *TOP1* and TATA-box binding protein (*TBP*) were used in studies of LPS

treatments in second trimester explants. The relative expression of target genes was

calculated by the 2-ΔΔCT method (Livak & Schmittgen, 2001). The primer sequences of

all the assessed genes are shown in Table 2.

Table 2. List of primers used in this study.

Primer name	Sequence	Reference
ACE2	Forward: 5'- GGAGTGATAGTGGTTGGCATTGTC -3	*
	Reverse: 5'-GCTAATATCGATGGAGGCATAAGGA-3'	
IL-6	Forward: 5'-TGCAGAAAAAGGCAAAGAAT-3'	(Lye *et al.*, 2019)
	Reverse: 5'-CTGACCAGAAGAAGGAATGC-3'	
IL-8	Forward: 5'-TGGGAACAAGAGGGCATCTG-3'	(Lye *et al.*, 2019)
	Reverse: 5'-CCACCACTGCATCAAATTCATG-3'	
CCL2	Forward: 5'-TTCATTCCCCAAGGGCTCGCTCA -3'	(Lye *et al.*, 2015)
	Reverse: 5'-AGCACAGATCTCCTTGGCCACAA -3'	
TNFα	Forward: 5'-CCTGGGGAACTCTTCCCTCTGGGG -3'	*
	Reverse: 5'-CAGGCGCCACCACGCTCTTC -3'	
TBP	Forward: 5'-TGC ACA GGA GCC AAG AGT GAA -3'	(Keidar *et al.*, 2005)
	Reverse: 5'-CAC ATC ACA GCT CCC CAC CA -3'	
YWHAZ	Forward: 5'-CCGCCAGGACAAACCAGTAT-3'	(Drewlo *et al.*, 2012)

	Reverse: 5'-CAC ATC ACA GCT CCC CAC CA-3'	
TOP1	Forward: 5'-GATGAACCTGAAGATGATGGC-3'	(Drewlo *et al.*, 2012)
	Reverse: 5'-TCAGCATCATCCTCATCTCG-3'	

*Gene specific primers were designed with Primer-BLAST (http://www.ncbi.nlm.nih.gov/tools/primer-blast).

Immunoblotting

Western blot analysis was conducted as previously described (Lye *et al.*, 2019) Briefly,

protein isolated from cultured cells was extracted by sonication using lysis buffer (1 mol/L

Tris-HCL pH 6.8, 2% SDS, 10% glycerol with added protease and phosphatase inhibitor

cocktail; Thermo Scientific). The protein concentration was determined with the Pierce

BCA Protein Assay kit (Thermo Scientific). Proteins were separated by electrophoresis

(30 µg 100 V, 1 h) using SDS polyacrylamide gels (8%). Proteins were then transferred

(10 min) to polyvinylidene fluoride (PVDF) membrane using Trans-Blot Turbo (Bio-Rad).

Membranes were blocked with skim milk (5%; 1 h at room temperature). The primary

antibodies used were anti-rabbit ACE2 (dilution 1:1000; Abcam, ab108209, Toronto, ON,

Canada) and anti-goat *β*-actin (dilution 1:2000; Santa Cruz Biotechnology, Dallas, TX,

USA). Blots were incubated with primary antibodies overnight at 4 °C. The PVDF

membranes were subsequently incubated for 1 h with HRP-linked anti-goat secondary

antibody (GE Healthcare Bio-Science, Baie d'Urfe, QC, Canada) at concentrations of

1:10,000. Protein-antibody complexes were detected by incubating (for 5 min) the PVDF

membranes with Laminate Crescendo Western HRP Substrate (Millipore, Oak Drive, CA,

USA) and chemiluminescence was detected under UV by using the ChemiDoc^TM MP

Imaging system (Bio-Rad). The protein band intensity was quantified using Image Lab^{TM}

software.

Immune cell isolation

Peripheral blood samples were collected prospectively into EDTA blood collection tubes

from pregnant women in the first trimester (10-14 gestational weeks) during the regular

antenatal visit. Monocytes and lymphocytes were isolated separately using the

RosetteSep Human Total Lymphocyte Enrichment Cocktail and the RosetteSep Human

Total Lymphocyte Enrichment Cocktail (both from Stemcell Technologies, BC, CA)

following manufacturer's instructions as described earlier (Paquette *et al.*, 2018).

RosetteSep technology uses high-density gradient centrifugation to generate a highly

purified and stable leukocyte fraction RNA expression studies. Following isolation, the

monocytes and lymphocytes were re-suspended in RPMI-1640 with 10% FBS. Primary

human neutrophils were isolated by Histopaque double density gradient method,

consisting of HISTOPAQUE®-1119 and HISTOPAQUE®-1077 (Sigma-Aldrich, MO,

USA). Neutrophils were collected, washed twice in HBSS+ and spun again (Amsalem *et*

al., 2014).

Flow cytometry

Direct immunofluorescence staining was performed using peripheral blood collected from

pregnant women at 10-14 weeks of pregnancy. In brief, the whole blood (50µl) was

stained with LIVE/DEAD® fixable cell stain kit (L/D-violet; Invitrogen) and then incubated

with human Fc block (BD Pharmingen) and incubated for 30 minutes. To detect the

expression of ACE2 protein, surface staining was conducted by Alexa Fluor® 700-

conjugated mouse anti-human ACE-2 (R&D Systems) and APC-H7 mouse anti-human

CD45 (BD Biosciences) antibodies. Cells were washed and resuspended in stabilizing

fixative buffer (BD Biosciences) to preserve immunofluorescence staining signals of

human blood.

Flow cytometric data were acquired with a Gallios flow cytometer (Beckman Coulter).

Data analyses were performed by FlowJo V10 (TreeStar) or Kaluza 2 (Beckman Coulter)

software. Only viable CD45+ blood cells were analyzed for their ACE2 expression.

Circulating lymphocytes, monocytes and granulocytes were recognized by their distinct

morphological features in the forward and side scatter distribution.

Statistical Analysis

All analyses were conducted blind to the experimental conditions. Data analyses

were performed with Prism version 8 (GraphPad Software Inc., San Diego, CA, USA)

qPCR data were assessed for normal distribution using D'Agostino and Pearson or the

Shapiro-Wilk test; outliers were identified using "QuickCalcs" Outlier calculator program

(version 7.0; GraphPad Software, Inc., San Diego, CA). Gene and protein expression,

number of macrophages, and maternal immune cell were analyzed using one-way

ANOVA followed by Tukey's multiple comparisons test. Results from LPS-treated

explants were assessed by paired t-test. Gene expression of the LPS treated explants

were normalized to their respected vehicle group at both 4 and 24 hours. Differences

were considered statistically significant when $p < 0.05$.

Author Contributions

Conceptualization: PL, CED, SGM, SJL; Funding acquisition: SJL, SGM;

Methodology: PL, CED, JZ, JN, GEI, SL; Project administration SGM, SJL; Supervision: SGM, SJL; Validation: PL, CED, JZ; Writing - original draft: PL, CED, HH, EB, JZ, YW; Writing - review & editing: CED, PL, HH, JN, YW, GEI, EB, SGM, SJL.

Acknowledgement

The authors thank the donors, RCWIH BioBank, the Lunenfeld-Tanenbaum Research Institute, and the Mount Sinai Hospital/UHN Department of Obstetrics and Gynaecology for the human specimens used in this study (http://biobank.lunenfeld.ca). We are grateful for the assistance provided by Mrs. Anna Dorogin in optimising immunostaining, Mrs. Elzbieta Matysiak-Zablocki with the isolation of granulocytes, monocytes and lymphocytes and Dr. Oksana Shynlova with the isolation of maternal immune cell protocols.

Additional Information

The authors report no conflict of interest.

E.B. is supported by the Coordenaçao de Aperfeiçoamento Pessoal de Nível Superior [CAPES]; finance code 001, CAPES-Print fellowship). S.J.L. is supported by a grant (FDN-143262) from the Canadian Institutes of Health Research (CIHR). S.G.M. is supported by a grant (FDN-148368) from the CIHR.

The funders had no role in the experimental design, data acquisition, analysis, and

interpretation or in the manuscript writing and conception of this study. The corresponding

authors had full access to all the data in the study and had final responsibility for the

decision to submit for publication.

Additional Information

Available from the authors upon reasonable request

References

Algarroba, G.N., Rekawek, P., Vahanian, S.A., Khullar, P., Palaia, T., Peltier, M.R., Chavez,
M.R. & Vintzileos, A.M. (2020) Visualization of SARS-CoV-2 virus invading the human
placenta using electron microscopy. *American journal of obstetrics and gynecology*.
576
577   Amsalem, H., Kwan, M., Hazan, A., Zhang, J., Jones, R.L., Whittle, W., Kingdom, J.C., Croy,
578   B.A., Lye, S.J. & Dunk, C.E. (2014) Identification of a novel neutrophil population:
579   proangiogenic granulocytes in second-trimester human decidua. *Journal of immunology
580   (Baltimore, Md. : 1950)*, **193**, 3070-3079.
581
582   Baud, D., Greub, G., Favre, G., Gengler, C., Jaton, K., Dubruc, E. & Pomar, L. (2020) Second-
583   Trimester Miscarriage in a Pregnant Woman With SARS-CoV-2 Infection. *Jama*, **323**,
584   2198-2200.
585
Bloise, E., Zhang, J., Nakpu, J., Hamada, H., Dunk, C.E., Li, S., Imperio, G.E., Nadeem, L.,
Kibschull, M., Lye, P., Matthews, S.G. & Lye, S.J. (2020) Expression of severe acute
respiratory syndrome coronavirus 2 cell entry genes, angiotensin-converting enzyme 2
and transmembrane protease serine 2, in the placenta across gestation and at the maternal-
fetal interface in pregnancies complicated by preterm birth or preeclampsia. *American
journal of obstetrics and gynecology*. S0002-9378(20)30884-X.
592
593   Blumberg, D.A., Underwood, M.A., Hedriana, H.L. & Lakshminrusimha, S. (2020) Vertical
594   Transmission of SARS-CoV-2: What is the Optimal Definition? *American journal of
595   perinatology*, **37**, 769-772.
596

Capobianco, G., Saderi, L., Aliberti, S., Mondoni, M., Piana, A., Dessole, F., Dessole, M.,
Cherchi, P.L., Dessole, S. & Sotgiu, G. (2020) COVID-19 in pregnant women: A
systematic review and meta-analysis. *European journal of obstetrics, gynecology, and*
reproductive biology, **252**, 543-558.

Cappelletti, M., Presicce, P. & Kallapur, S.G. (2020) Immunobiology of Acute
Chorioamnionitis. *Front Immunol*, **11**, 649-649.

Cardenas, I., Mor, G., Aldo, P., Lang, S.M., Stabach, P., Sharp, A., Romero, R., Mazaki-Tovi, S.,
Gervasi, M. & Means, R.E. (2011) Placental viral infection sensitizes to endotoxin-
induced pre-term labor: a double hit hypothesis. *American journal of reproductive*
immunology (New York, N.Y. : 1989), **65**, 110-117.

Chen, H., Guo, J., Wang, C., Luo, F., Yu, X., Zhang, W., Li, J., Zhao, D., Xu, D., Gong, Q.,
Liao, J., Yang, H., Hou, W. & Zhang, Y. (2020) Clinical characteristics and intrauterine
vertical transmission potential of COVID-19 infection in nine pregnant women: a
retrospective review of medical records. *Lancet (London, England)*, **395**, 809-815.

Choudhury, R.H., Dunk, C.E., Lye, S.J., Harris, L.K., Aplin, J.D. & Jones, R.L. (2019) Decidual
leucocytes infiltrating human spiral arterioles are rich source of matrix metalloproteinases
and degrade extracellular matrix in vitro and in situ. *American journal of reproductive*
immunology (New York, N.Y. : 1989), **81**, e13054.

Crackower, M., Sarao, R., Oudit, G., Yagil, C., Kozieradzki, I., Scanga, S., Oliveira-dos-Santos,
A., Costa, J., Zhang, L., Pei, Y., Scholey, J., Ferrario, C., Manoukian, A., Chappell, M.,
Backx, P., Yagil, Y. & Penninger, J. (2002) Angiotensin-converting enzyme 2 is an
essential regulator of heart function. *Nature*, **417**, 822-828.

Dong, L., Tian, J., He, S., Zhu, C., Wang, J., Liu, C. & Yang, J. (2020) Possible Vertical
Transmission of SARS-CoV-2 From an Infected Mother to Her Newborn. *Jama*, **323**,
1846-1848.

Drewlo, S., Levytska, K. & Kingdom, J. (2012) Revisiting the housekeeping genes of human
placental development and insufficiency syndromes. *Placenta*, **33**, 952-954.

Dunk, C., Kwan, M., Hazan, A., Walker, S., Wright, J.K., Harris, L.K., Jones, R.L., Keating, S.,
Kingdom, J.C.P., Whittle, W., Maxwell, C. & Lye, S.J. (2019) Failure of Decidualization
and Maternal Immune Tolerance Underlies Uterovascular Resistance in Intra Uterine
Growth Restriction. *Frontiers in Endocrinology*, **10**.

Dunk, C.E., Pappas, J.J., Lye, P., Kibschull, M., Javam, M., Bloise, E., Lye, S.J., Szyf, M. &
Matthews, S.G. (2018) P-Glycoprotein (P-gp)/ABCB1 plays a functional role in
extravillous trophoblast (EVT) invasion and is decreased in the pre-eclamptic placenta.
Journal of cellular and molecular medicine, **22**, 5378-5393.

Facchetti, F., Bugatti, M., Drera, E., Tripodo, C., Sartori, E., Cancila, V., Papaccio, M.,
643   Castellani, R., Casola, S., Boniotti, M.B., Cavadini, P. & Lavazza, A. (2020) SARS-
644   CoV2 vertical transmission with adverse effects on the newborn revealed through
645   integrated immunohistochemical, electron microscopy and molecular analyses of
646   Placenta. *EBioMedicine*, **59**, 102951.

648   Francis, F., Bhat, V., Mondal, N., Adhisivam, B., Jacob, S., Dorairajan, G. & Harish, B.N.
649   (2019) Fetal inflammatory response syndrome (FIRS) and outcome of preterm neonates -
650   a prospective analytical study. *The journal of maternal-fetal & neonatal medicine : the*
651   *official journal of the European Association of Perinatal Medicine, the Federation of*
652   *Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet*, **32**,
653   488-492.

655   Glauser, M.P., Zanetti, G., Baumgartner, J.D. & Cohen, J. (1991) Septic shock: pathogenesis.
656   *Lancet (London, England)*, **338**, 732-736.

658   Gomez-Lopez, N., Romero, R., Maymon, E., Kusanovic, J.P., Panaitescu, B., Miller, D., Pacora,
659   P., Tarca, A.L., Motomura, K., Erez, O., Jung, E., Hassan, S.S. & Hsu, C.D. (2019)
660   Clinical chorioamnionitis at term IX: in vivo evidence of intra-amniotic inflammasome
661   activation. *Journal of perinatal medicine*, **47**, 276-287.

663   Gomez-Lopez, N., Romero, R., Xu, Y., Leng, Y., Garcia-Flores, V., Miller, D., Jacques, S.M.,
664   Hassan, S.S., Faro, J., Alsamsam, A., Alhousseini, A., Gomez-Roberts, H., Panaitescu,
665   B., Yeo, L. & Maymon, E. (2017) Are amniotic fluid neutrophils in women with
666   intraamniotic infection and/or inflammation of fetal or maternal origin? *American journal*
667   *of obstetrics and gynecology*, **217**, 693.e691-693.e616.

669   Hamilton, S., Oomomian, Y., Stephen, G., Shynlova, O., Tower, C.L., Garrod, A., Lye, S.J. &
670   Jones, R.L. (2012) Macrophages infiltrate the human and rat decidua during term and
671   preterm labor: evidence that decidual inflammation precedes labor. *Biology of*
672   *reproduction*, **86**, 39.

674   Hamming, I., Timens, W., Bulthuis, M.L.C., Lely, A.T., Navis, G.J. & van Goor, H. (2004)
675   Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A
676   first step in understanding SARS pathogenesis. *J Pathol*, **203**, 631-637.

678   Jia, H.P., Look, D.C., Shi, L., Hickey, M., Pewe, L., Netland, J., Farzan, M., Wohlford-Lenane,
679   C., Perlman, S. & McCray, P.B., Jr. (2005) ACE2 receptor expression and severe acute
680   respiratory syndrome coronavirus infection depend on differentiation of human airway
681   epithelia. *J Virol*, **79**, 14614-14621.

683   Karimi-Zarchi, M., Neamatzadeh, H., Dastgheib, S.A., Abbasi, H., Mirjalili, S.R., Behforouz, A.,
684   Ferdosian, F. & Bahrami, R. (2020) Vertical Transmission of Coronavirus Disease 19
685   (COVID-19) from Infected Pregnant Mothers to Neonates: A Review. *Fetal and*
686   *pediatric pathology*, **39**, 246-250.
687

688 Keidar, S., Gamliel-Lazarovich, A., Kaplan, M., Pavlotzky, E., Hamoud, S., Hayek, T., Karry, R.
689   & Abassi, Z. (2005) Mineralocorticoid receptor blocker increases angiotensin-converting
690   enzyme 2 activity in congestive heart failure patients. *Circulation research*, **97**, 946-953.
691

692 Kim, C.J., Romero, R., Chaemsaithong, P., Chaiyasit, N., Yoon, B.H. & Kim, Y.M. (2015)
693   Acute chorioamnionitis and funisitis: definition, pathologic features, and clinical
694   significance. *American journal of obstetrics and gynecology*, **213**, S29-52.
695

696 Knöfler, M., Haider, S., Saleh, L., Pollheimer, J., Gamage, T. & James, J. (2019) Human
697   placenta and trophoblast development: key molecular mechanisms and model systems.
698   *Cellular and molecular life sciences : CMLS*, **76**, 3479-3496.
699

700 Kwon, J.Y., Romero, R. & Mor, G. (2014) New insights into the relationship between viral
701   infection and pregnancy complications. *American journal of reproductive immunology*
702   *(New York, N.Y. : 1989)*, **71**, 387-390.
703

704 Li, F. (2016) Structure, Function, and Evolution of Coronavirus Spike Proteins. *Annual review of*
705   *virology*, **3**, 237-261.
706

707 Li, G., He, X., Zhang, L., Ran, Q., Wang, J., Xiong, A., Wu, D., Chen, F., Sun, J. & Chang, C.
708   (2020a) Assessing ACE2 expression patterns in lung tissues in the pathogenesis of
709   COVID-19. *J Autoimmun*, **112**, 102463-102463.
710

711 Li, M., Chen, L., Zhang, J., Xiong, C. & Li, X. (2020b) The SARS-CoV-2 receptor ACE2
712   expression of maternal-fetal interface and fetal organs by single-cell transcriptome study.
713   *PloS one*, **15**, e0230295.
714

715 Liu, X., Yin, S., Chen, Y., Wu, Y., Zheng, W., Dong, H., Bai, Y., Qin, Y., Li, J., Feng, S. &
716   Zhao, P. (2018) LPS-induced proinflammatory cytokine expression in human airway
717   epithelial cells and macrophages via NF-κB, STAT3 or AP-1 activation. *Molecular*
718   *medicine reports*, **17**, 5484-5491.
719

720 Livak, K.J. & Schmittgen, T.D. (2001) Analysis of relative gene expression data using real-time
721   quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods (San Diego, Calif.)*, **25**,
722   402-408.
723

724 Lye, P., Bloise, E., Javam, M., Gibb, W., Lye, S.J. & Matthews, S.G. (2015) Impact of bacterial
725   and viral challenge on multidrug resistance in first- and third-trimester human placenta.
726   *The American journal of pathology*, **185**, 1666-1675.
727

728 Lye, P., Bloise, E., Nadeem, L., Peng, C., Gibb, W., Ortiga-Carvalho, T.M., Lye, S.J. &
729   Matthews, S.G. (2019) Breast Cancer Resistance Protein (BCRP/ABCG2) Inhibits Extra
730   Villous Trophoblast Migration: The Impact of Bacterial and Viral Infection. *Cells*, **8**.
731

Nadeem, L., Brkic, J., Chen, Y.F., Bui, T., Munir, S. & Peng, C. (2013) Cytoplasmic
mislocalization of p27 and CDK2 mediates the anti-migratory and anti-proliferative
effects of Nodal in human trophoblast cells. *Journal of cell science*, **126**, 445-453.

Paquette, A.G., Shynlova, O., Kibschull, M., Price, N.D. & Lye, S.J. (2018) Comparative
analysis of gene expression in maternal peripheral blood and monocytes during
spontaneous preterm labor. *American journal of obstetrics and gynecology*, **218**,
345.e341-345.e330.

Pringle, K., Tadros, M., Callister, R.J. & Lumbers, E. (2011a) The expression and localization of
the human placental prorenin/renin-angiotensin system throughout pregnancy: Roles in
trophoblast invasion and angiogenesis? *Placenta*, **32**, 956-962.

Pringle, K.G., Tadros, M.A., Callister, R.J. & Lumbers, E.R. (2011b) The expression and
localization of the human placental prorenin/renin-angiotensin system throughout
pregnancy: roles in trophoblast invasion and angiogenesis? *Placenta*, **32**, 956-962.

Qiao, J. (2020) What are the risks of COVID-19 infection in pregnant women? *Lancet (London,*
England), **395**, 760-762.

Rasmussen, S.A., Smulian, J.C., Lednicky, J.A., Wen, T.S. & Jamieson, D.J. (2020) Coronavirus
Disease 2019 (COVID-19) and pregnancy: what obstetricians need to know. *American*
journal of obstetrics and gynecology, **222**, 415-426.

Redline, R.W., Faye-Petersen, O., Heller, D., Qureshi, F., Savell, V. & Vogler, C. (2003)
Amniotic infection syndrome: nosology and reproducibility of placental reaction patterns.
Pediatric and developmental pathology : the official journal of the Society for Pediatric
Pathology and the Paediatric Pathology Society, **6**, 435-448.

Romero, R., Salafia, C.M., Athanassiadis, A.P., Hanaoka, S., Mazor, M., Sepulveda, W. &
Bracken, M.B. (1992) The relationship between acute inflammatory lesions of the
preterm placenta and amniotic fluid microbiology. *American journal of obstetrics and*
gynecology, **166**, 1382-1388.

Salio, C., Lossi, L., Ferrini, F. & Merighi, A. (2005) Ultrastructural evidence for a pre- and
postsynaptic localization of full-length trkB receptors in substantia gelatinosa (lamina II)
of rat and mouse spinal cord. *The European journal of neuroscience*, **22**, 1951-1966.

Schwartz, D.A. (2020) An Analysis of 38 Pregnant Women with COVID-19, Their Newborn
Infants, and Maternal-Fetal Transmission of SARS-CoV-2: Maternal Coronavirus
Infections and Pregnancy Outcomes. *Archives of pathology & laboratory medicine*.

Shah, P.S., Diambomba, Y., Acharya, G., Morris, S.K. & Bitnun, A. (2020) Classification
system and case definition for SARS-CoV-2 infection in pregnant women, fetuses, and
neonates. *Acta obstetricia et gynecologica Scandinavica*, **99**, 565-568.
777

778 Shynlova, O., Nadeem, L., Zhang, J., Dunk, C. & Lye, S. (2020) Myometrial activation: Novel
779   concepts underlying labor. *Placenta*, **92**, 28-36.
780

781 Silasi, M., Cardenas, I., Kwon, J.Y., Racicot, K., Aldo, P. & Mor, G. (2015) Viral infections
782   during pregnancy. *American journal of reproductive immunology (New York, N.Y. :*
783   *1989)*, **73**, 199-213.
784

785 Valdés, G., Neves, L.A., Anton, L., Corthorn, J., Chacón, C., Germain, A.M., Merrill, D.C.,
786   Ferrario, C.M., Sarao, R., Penninger, J. & Brosnihan, K.B. (2006) Distribution of
787   angiotensin-(1-7) and ACE2 in human placentas of normal and pathological pregnancies.
788   *Placenta*, **27**, 200-207.
789

790 Vickers, C., Hales, P., Kaushik, V., Dick, L., Gavin, J., Tang, J., Godbout, K., Parsons, T.,
791   Baronas, E., Hsieh, F., Acton, S., Patane, M., Nichols, A. & Tummino, P. (2002)
792   Hydrolysis of biological peptides by human angiotensin-converting enzyme-related
793   carboxypeptidase. *The Journal of biological chemistry*, **277**, 14838-14843.
794

795 Wan, Y., Shang, J., Graham, R., Baric, R.S. & Li, F. (2020) Receptor Recognition by the Novel
796   Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of
797   SARS Coronavirus. *Journal of Virology*, **94**, e00127-00120.
798

799 Wang, S., Guo, L., Chen, L., Liu, W., Cao, Y., Zhang, J. & Feng, L. (2020) A Case Report of
800   Neonatal 2019 Coronavirus Disease in China. *Clinical Infectious Diseases*.
801

802 Zamaniyan, M., Ebadi, A., Aghajanpoor, S., Rahmani, Z., Haghshenas, M. & Azizi, S. (2020)
803   Preterm delivery, maternal death, and vertical transmission in a pregnant woman with
804   COVID-19 infection. *Prenatal diagnosis*.
805

806 Zeng, H., Xu, C., Fan, J., Tang, Y., Deng, Q., Zhang, W. & Long, X. (2020) Antibodies in
807   Infants Born to Mothers With COVID-19 Pneumonia. *Jama*, **323**, 1848-1849.
808

809 Zhang, H., Penninger, J.M., Li, Y., Zhong, N. & Slutsky, A.S. (2020a) Angiotensin-converting
810   enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential
811   therapeutic target. *Intensive Care Med*, **46**, 586-590.
812

813 Zhang, L., Jiang, Y., Wei, M., Cheng, B.H., Zhou, X.C., Li, J., Tian, J.H., Dong, L. & Hu, R.H.
814   (2020b) [Analysis of the pregnancy outcomes in pregnant women with COVID-19 in
815   Hubei Province]. *Zhonghua fu chan ke za zhi*, **55**, 166-171.